Overview of bio­med­i­cine mar­ket in Chi­na, webi­nar

Busi­ness Fin­land organ­is­es a webi­nar that offers Finnish com­pa­nies an oppor­tu­ni­ty to explore the accel­er­at­ing biotech sec­tor in China—an indus­try where inno­va­tion is rapid­ly advanc­ing and gain­ing inter­na­tion­al acclaim.

In recent years, Chi­na’s gov­ern­ment has been enact­ing poli­cies that have stead­fast­ly steered towards bol­ster­ing domes­tic biotech inno­va­tions. Chi­na’s biotech sec­tor is rapid­ly ascend­ing the glob­al ranks in inno­va­tion. There are com­pelling signs that indi­cate a shrink­ing gap between China’s biotech inno­va­tion and that of the estab­lished glob­al lead­ers in the West.

Time: 5 March 2025, 8:30–10:30 (Finnish time)

Place: Online

Reg­is­tra­tion

Remark­ably, in 2023, the U.S. FDA approved three inno­v­a­tive Chi­nese drugs, herald­ing an era of inter­na­tion­al recog­ni­tion for Chi­na’s phar­ma­ceu­ti­cal inge­nu­ity. Fur­ther­more, the fre­quen­cy of out-licens­ing agree­ments by Chi­nese enti­ties has surged, climb­ing from a mere 15 in 2019 to an impres­sive 33 agree­ments in 2023, with oncol­o­gy wit­ness­ing the most sig­nif­i­cant upswing. These part­ner­ships encom­pass a diverse array of ther­a­peu­tic approach­es, includ­ing both small mol­e­cules and com­plex bio­log­ics. Notably, clin­i­cal tri­als in Chi­na have sky­rock­et­ed, more than dou­bled from 2017 to 2021.

The piv­otal ques­tion then aris­es: what oppor­tu­ni­ties does this land­scape present for Fin­land’s inter­face with Chi­na’s thriv­ing biotech ecosys­tem? Delv­ing into viable mar­ket entry tac­tics, we con­tem­plate how Finnish enter­pris­es can poise them­selves for suc­cess­ful mar­ket inte­gra­tion and sus­tained growth.

Ms. Helen Chen, who serves as the Glob­al Sec­tor Co-Head for Health­care and Life Sci­ences for the Asia Pacif­ic, along­side her role as a Greater Chi­na Man­ag­ing Part­ner at L.E.K. Con­sult­ing, will illu­mi­nate the intri­ca­cies involved.

A rep­re­sen­ta­tive of a pio­neer­ing Chi­nese biotech enter­prise will share the invalu­able insights gleaned from nav­i­gat­ing Chi­na’s dynam­ic biotech sec­tor. Com­ple­men­tar­i­ly, a Finnish com­pa­ny will present their unique nar­ra­tive of engage­ment with Chi­na’s biotech sphere.

Speak­er

Helen Chen is Glob­al Sec­tor Co-Head for Health­care and a Greater Chi­na Man­ag­ing Part­ner of L.E.K. Con­sult­ing based in Shang­hai. Helen was a mem­ber of L.E.K.’s Glob­al Lead­er­ship Team from 2012 to 2016. She is also a Direc­tor of the firm’s Asia-Pacif­ic Life Sci­ences Cen­tre of Excel­lence. Helen was named one of Con­sult­ing magazine’s Glob­al Lead­ers in Con­sult­ing in 2019.

Read more infor­ma­tion about the webi­nar.

Con­tact per­son

Ms. Sanori­ta Li

Senior Advi­sor

sanorita.li (at) businessfinland.fi

Source: Busi­ness Fin­land